ExpreS2ion further strengthens leadership team with appointment of Chief Scientific Officer
Hørsholm, Denmark, January 3, 2023 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces the appointment of Dr. Farshad Guirakhoo as the Company’s new Chief Scientific Officer (CSO). Dr. Guirakhoo has more than 30 years of broad translational research experience in the vaccine development field, and will be responsible for directing the development of the discovery and preclinical strategies and plans that support ExpreS2ion’s development pipeline of unique vaccine assets, including managing the progression of ExpreS2ion’s vaccine technology platform. Dr. Guirakhoo starts his employment on January 16, 2023 at ExpreS2ion’s headquarters in Hørsholm, Denmark.
CEO Bent U. Frandsen comments:
“It is with great pleasure that I welcome Farshad to ExpreS2ion. Farshad’s decades of experience in research & development will be invaluable in steering the early stage development of ExpreS2ion's infectious disease and oncology focused pipeline and technology platform development.”
CSO Dr. Farshad Guirakhoo comments:
“I am truly excited to join Bent and his team of highly skilled scientists, who have developed one of the currently most exciting pipelines in the biotech industry with unique vaccine candidates to prevent COVID-19 and treat breast cancer. I am looking forward to create further value out of ExpreS2ion’s vaccine technology platform.”
Dr. Farshad Guirakhoo joins from his recent positions as Senior Advisor Vaccine Research and Development and CSO of Vaxxinity, Inc. (NASDAQ: VAXX), which is headquartered in Dallas, Texas. In 2014, Dr. Guirakhoo was named as no. 22 in The Most Influential People in Vaccines. He is the co-inventor of the ChimeriVax™-technology platform, the world’s first recombinant viral vector platform that was approved for any human vaccine. Dr. Guirakhoo has broad experience in the application of genetics, gene expression technologies and molecular virology for the construction and production of recombinant proteins, human antibodies and attenuated viral vectored vaccines for prevention and treatment of infectious diseases and cancers. He is the author of over 100 peer-reviewed publications and holds dozens of issued patents. Dr. Guirakhoo received his Ph.D. in Virology from the Medical University of Vienna, Austria, holds an M.Sc. in Genetics from the International Institute for Biophysics and Biochemistry at the University of Tehran and a B.Sc. in Biology from the National University of Iran. He has been awarded the National Research Council Post-Doctorate Award and studied at the CDC, Division of Vector-Borne Infectious Diseases, in Fort Collins, CO, United States.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
This press release constitutes inside information that ExpreS2ion Biotech Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company’s news distributor, Cision, at the publication of this press release.
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.
Tags: